Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > National Forensic Laboratory Information System (NFLIS)

National Forensic Laboratory Information System (NFLIS)

Overview

The DEA National Forensic Laboratory Information System (NFLIS) systematically collects results from drug chemistry analyses conducted by state, local and federal forensic laboratories across the country. As a national drug forensic laboratory reporting system, NFLIS provides timely and detailed analytical results of drugs seized by law enforcement. It is a unique source of information for monitoring and understanding drug abuse and trafficking in the United States, including the diversion of legally manufactured drugs into illegal markets. Findings from NFLIS can also supplement existing drug data sources, including information from drug demand surveys and drug testing programs.

Over 300 state and local forensic laboratories in the United States perform nearly two million drug analyses each year. As of April 2017, 50 state laboratory systems and 100 local laboratory systems, representing 287 individual laboratories, are participating in NFLIS. In 2015, approximately 1.5 million drug analysis records were reported to NFLIS. This information is made available through semiannual, annual, and special reports. These reports include findings on major drug categories such as narcotic analgesics, depressants and tranquilizers, hallucinogens, anabolic steroids, and stimulants. They provide statistically representative national and regional drug item estimates for the most frequently identified drugs. National case estimates for the most frequently identified drugs are also presented.

NFLIS is one resource of information utilized by DEA to carry out its core mission. The NFLIS information system supports DEA's ability to track national, regional, and local drug patterns, including providing timely and geographically specific information on emerging drug problems. Over the next several years, DEA will seek to expand the NFLIS program to include all federal, state, and local laboratories that perform drug chemical analyses.

NFLIS Program Expansion

Over the next few years, the NFLIS program will expand to include two additional continuous drug surveillance programs that collect drug-related mortality data from medical examiner and coroner offices (ME/Cs) and drug testing results from toxicology laboratories to supplement and complement the current information from drug cases submitted to and analyzed by the Nation’s forensic laboratories.

Over the next several months, DEA will be conducting the NFLIS Medical Examiner/Coroner Office Survey and the NFLIS Toxicology Laboratory Survey. The information gathered during these two surveys will inform the data surveillance system that will be launched in 2018. Results from these two surveys will be released via a report that provides aggregated statistics, as DEA has done with the NFLIS Survey of Crime Laboratory Drug Chemistry Sections (e.g., see the 2013 report).

Contact Us

Drug Enforcement Administration DeMia P. Pressley
Diversion Control Division
Drug & Chemical Evaluation Section
8701 Morrissette Drive
Springfield, Virginia 22152
Project Officer
(202) 307-7183 (Phone)
(202) 353-1263 (Fax)
NFLIS@usdoj.gov


Publications

The following are publications produced by the NFLIS project. These include annual, midyear, and special reports. All PDF reports require Adobe Acrobat Reader for viewing.

2017

Brief: Fentanyl, 2001–2015

2016

Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2013–2015

2015 Annual Report

2015 Midyear Report

2015

2014 Annual Report

2014 Midyear Report (Revised March 2016)

Statistical Methodology, 2014

Special Report: Opiates and Related Drugs Reported in NFLIS, 2009-2014 (Revised February 2016)

Special Report: Benzodiazepines Reported in NFLIS, 2009–2014

2014

2013 Annual Report

2013 Midyear Report

2013 Survey of Crime Laboratory Drug Chemistry Sections

Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2010–2013

2013

2012 Annual Report

2012 Midyear Report

2012

2011 Annual Report

2011 Midyear Report

Special Report: ADD/ADHD Stimulants in NFLIS, 2007-2011

Special Report: Emerging 2C-Phenethylamines, Piperazines, and Tryptamines in NFLIS, 2006-2011

2011

NFLIS Estimates Methodology

2010 Annual Report

2010 Midyear Report

Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010

2010

2009 Annual Report

2009

2009 Midyear Report

2008 Annual Report

Special Report: Methadone and Buprenorphine, 2003-2008

2008

2008 Midyear Report

2007 Annual Report

2007

2007 Midyear Report

2006 Annual Report

Special Report: Fentanyl 2003-2006

2006

2006 Midyear Report

2005 Annual Report

Special Report: Controlled Substance Prescription Drugs, 2001-2005

2005

2005 Midyear Report

2004 Annual Report

Special Report: Synthetic Drugs, 2001-2004

2004

2004 Midyear Report

2003 Annual Report

2003

2003 Midyear Report

2002 Annual Report

Special Report: Narcotic Analgesics 2001-2003

2002

2002 4th Quarterly Report

2002 3rd Quarterly Report

2002 2nd Quarterly Report

2002 1st Quarterly Report

2001 Annual Report

2001

2001 4th Quarterly Report

2001 3rd Quarterly Report

2001 2nd Quarterly Report

2001 1st Quarterly Report

2000 Annual Report

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility